| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
For developing iPS cell disease model of Stage 4s neuroblasoma, we converted normal human fibroblast into IPS cells. Moreover, we tried to differentiate iPS cell to neural crest stem cell, but it failed.
Next, we tried to co-culture hMSC and human neuroblastoma cell line in order to clarify the differentiation of the neurolbastoma cells. Finally, we observed the neurite elongation of neuroblastoma cells.
From this results, we are going to analyze the therapeutic potential of hMSCs as novel diffrentiation therapy of neurolbastoma.
|
